Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2016-02-10 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings
2016-02-10 Hebrew (modern)
Immediate Report
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content states: 'Attached hereto is a report on *receiving a patent from the Israeli Patent Office to it's lead drug candidate hCDR1 for the treatment of lupus.*' This structure—a brief announcement referencing an attached or linked document detailing a specific event (patent receipt)—fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Since it is a specific regulatory update that isn't a director's dealing, dividend, or capital change, and it's not a full financial report (10-K, IR), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (1717 chars), supporting the idea that it is an announcement rather than the full report itself.
2016-02-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It contains a press release announcing the granting of a patent for their lead drug candidate hCDR1, details about the drug, the market, and company background. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is primarily an announcement of a corporate development (patent grant) and includes forward-looking statements. It is not an earnings release, annual report, or interim report. It is not a regulatory certification or officer attestation. The document is longer than 5,000 characters and contains substantive information, but it is essentially a corporate news announcement filed on Form 6-K. Form 6-K filings are generally considered Regulatory Filings (RNS) as they cover miscellaneous reports by foreign private issuers that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-02-10 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the U.S. SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It is a report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for the month of January 2016. The content is a corporate announcement about joining the Lupus Foundation of America's Corporate Advisory Council and includes forward-looking statements and company background. There are no financial statements or detailed financial data presented. Form 6-K filings are typically periodic reports by foreign private issuers to disclose material information and are not annual or interim financial reports themselves. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other specific categories.
2016-01-27 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed by XTL Biopharmaceuticals Ltd. It explicitly states: 'Attached hereto is a report on *acceptance of invitation to join the Lupus Foundation of America’s (LFA) Corporate Advisory Council (CAC) as of January 2016.*' and references an attached PDF file. The document itself is very short (1731 chars) and serves primarily to announce the publication of an attached report/update regarding an advisory council acceptance. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the release or publication of company reports, rather than the full content of a major periodic report (like 10-K or IR). Since it is an announcement of a specific, non-standard update, RPA is the most appropriate classification over the general fallback RNS.
2016-01-27 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer submitted pursuant to the Securities Exchange Act of 1934. It contains a corporate announcement about joining the Lupus Foundation of America's Corporate Advisory Council and provides business updates related to their lead drug candidate and upcoming clinical trials. There are no detailed financial statements or comprehensive financial performance data typical of annual or interim reports. The document is a regulatory filing providing material information but not a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 6-K that do not fit other categories.
2016-01-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.